Dyskinesias are involuntary abnormal movements of the body, most often in the face, arms, or legs. The movements may be jerky and unpredictable, or slow and writhing. They can be continuous, or come and go, and can be mild or severe. Dyskinesias are usually due to prolonged use of certain antiparkinsonian medications, but they can also occur with viral or toxic exposures, as part of other neurological disorders, or due to genetic diseases such as Huntington’s or Wilson’s disease, or due to certain pregnancy hormones. In some cases, drugs like PCP and cocaine can cause dyskinesia. The most common type of drug-induced dyskinesia is tardive dyskinesia, which is most often associated with antipsychotic medications. These medications can weaken or block the neurotransmitter dopamine, which helps regulate movement. When too much dopamine is blocked, movement can become jerky and unpredictable. Treatment for dyskinesia depends on the cause. If the disorder is caused by a drug, the drug should be discontinued or the dosage reduced. The doctor may prescribe drugs such as anticholinergic, sedatives or benzodiazepines to reduce muscle spasms, or levodopa and other dopaminergic medications to increase dopamine levels. In many cases, the movements of dyskinesia can be reduced with physical therapy, occupational therapy, and other therapies aimed at improving motor control and muscle strength, such as yoga and tai chi. In severe cases, surgery may be necessary to remove the offending nerves or parts of the brain that are causing the disorder. There is currently no cure for dyskinesia, but there are treatments that can help manage the symptoms. With proper treatment, people with dyskinesia can find relief from their symptoms and live a normal life.
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Modeling early neurologic trajectories after elevated leg positioning (ELP): A secondary analysis of the LEG-UP randomized feasibility study
Kayode Ahmed, The University of Texas MD Anderson Cancer Center, United States
Title : Neuro-exergaming for non-verbal autism spectrum: A case study of neuropsychological function after 15 sessions of pedal-n-play iPACES
Cay Anderson Hanley, iPACES, United States
Title : Prescribing joy: The importance of integrating memory cafes into dementia care
Saul Beaumont, Massachusetts Advisory Council on Alzheimer's Disease and All Other Dementias, United States